An American multinational pharmaceutical, medical devices, and consumer packaged goods manufacturer founded in 1883. The corporation includes some 250 subsidiary companies with operations in over 57 countries and products sold in over 175 countries. A suit brought by the United States Department of Justice in 2009 alleges that the company from 1999 to 2004 illegally marketed second-rate drugs including anti-psychotics to All-Care, a pharmacy chain that dispersed the drugs in nursing homes.
In winter of 2009, in an effort to clean up their image, Rutger-Millan announced they will start to fund a research group to conduct studies in neurogenesis, the method by which stem-cells can be used to re-grow dead brain tissue and potentially save the lives of thousands of patients around the world suffering from traumatic brain injuries.
Corporate Headquarters: Brunswick, New Jersey
Pharmaceutical & Medical Research Facilities:
Las Cruces, New Mexico
Corpus Christi, Texas
Stem cell research is controversial in itself. The main goal behind embryonic stem cell research is to find new and innovative ways to grow the biological cells, isolated from the inner cell mass of blastcycsts, into the various specialized cells found in the human body. In January of 2009, the USDA approved the first human trials of treatments using embryonic stem cells but unbeknownst to the public, three medical titans of the industry had been researching the use of embryonic stem cells in secrecy.
Records indicate Rutger-Millan, Whitesand Inc., and Biolife Medical had been conducting studies with embryonic stem cells since 1999.
Whitesand initially focused their research on the use of stem cells to treat various forms of lung and stomach cancer while Rutger-Millan and Biolife expanded their study to include cartilage regeneration in human joints. A clandestine war began between 1999-2009 as the three companies raced to out-perform each other in the area of stem cell research.
April 1999 - Word was leaked to Whitesand that Rutger-Millan was working on a controversial study in stem cells and their attempt to re-grow dead brain tissue.
May 2009 - Whitesand and Biolife go public with their stem cell research programs but hide the depth of their neurogenesis research. Whitesand president and CEO Pierre Montblanc sends scouts to recruit three of the leading neurologists working at Biolife, poaching them and turning them to Whitesand.
September 2009 - Photographs of Rutger-Millan's now infamous "organ farms" are leaked to the public from an unnamed inside source and the company faces a backlash from the public. The photographs show mass collection of bodies that the heads of research claim were all legally left to scientific research by the deceased. The majority of bodies were decapitated, leading the media into a feeding frenzy. Speculation abounds and Rutger-Millan releases a press statement explaining to the public what they've endeavored to achieve in the field of neurogenesis. At around the same time, Biolife and Whitesand up their security and establish a protocol for emergency leaks called "Code White," a predecessor to the Code Black protocols that would be used three years later.
The top executives within Rutger-Millan begin weeding out their company for leaks, suspecting that Whitesand was somehow able to turn somebody in their medical research department and use them to gain valuable insider information.
Feburary 2010 - Shortly after Rutger-Millan releases a statement "coming clean" about their plans for neurogenesis research, the controversy over abates - for the time being.
June 2010 - Without warning, Biolife suddenly releases a press statement claiming they are shutting down their neurogenesis research. Though they do not specifically state reasons for shutting down, conspiracy theorists point fingers at the bullying tactics of Whitesand, claiming that aggressive attacks by Pierre Montblanc and his effective poaching of Biolife scientists forced the company to cease its research.
March 2011 - Rutger-Millan and Whitesand both begin pushing the boundaries of brain tissue and stem cell research. Both companies begin experimenting with what they dub "reanimation research" by attempting to regrow the brains of comatose head trauma patients. The patients are kept in a state of suspended animation while their braincells are regrown. Once that process is complete, they theorize that the bodies can be reanimated and the patient can be brought back to life.
April 2012 - After 3 years, the reanimation process is a success. Rutger-Millan facilities in Corpus Christi, Texas are the first to successfully 're-awaken' a comatose patient whose brain tissue was regrown through the neurogenesis process. Once the procedure is complete, word traveled to facilities in Oceanside, California and Los Cruces, New Mexico. The procedure is replicated successfully in all three facilities with multiple comatose subjects being re-awoken - and that's when things turn ugly.
THE INEVITABLE COLLISION
3 in 4 human beings are carrying a genetic mutation, a dormant virus, or a genetically altered parasite. These humans can live and die without realizing that anything is wrong with them, without ever knowing their internal hard-wiring has been tampered with. These human beings were also reanimated in Rutger-Millan's experiments but the embryonic cells used to regrow their brain tissue mutated in unpredictable ways and the effects were catastrophic. Instead of healthy, living people, these reanimated patients became shuffling, mindless versions of their former selves. In other words, they were zombies. The patients were highly aggressive and began attacking researchers in the Rutger-Millan facilities. Within a few short hours the attacks spread outward beyond their isolated facilities and the media jumped on the story, detailing riots in major border cities between Mexico and the United States.